ROCKVILLE, MD, USA I April 10, 2014 I Precision Biologics is pleased to announce the continuation of encouraging clinical data from its ongoing Phase 1-2a study utilizing its novel monoclonal antibody NPC-1C. The data was presented by the investigators from the University of Texas Southwestern Medical Center collaboration with Johns Hopkins Hospital and Duke University Medical Center at the AACR Annual meeting on April 9, 2014 in San Diego, CA. NEO-102 is a reformulation of NPC-1C with improved productivity, stability, and safety. Thus far, 16 subjects with refractory metastatic pancreatic and colorectal cancer have been treated with the NEO-102 version of NPC-1C. Despite advanced disease in this patient population, preliminary signs of activity based on stabilization of disease have been observed in 5/9 (56%) of patients evaluable for response. Thirteen of 16 patients remain alive on study. Based on these results, the study has been expanded and statistically powered to include chemotherapy refractory metastatic patients: 43 colorectal cancer and 30 pancreatic cancer. In addition, there is an ongoing randomized study using gemcitabine and abraxane with or without NEO-102 in Folfirinox refractory advanced pancreatic cancer patients. Assessment of immune correlates of response with ADCC is underway.
Precision Biologics
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. For more information visit www.precision–biologics.com.
SOURCE: Precision Biologics
